IPOs for biotech companies: the Euronext option

IPOs in Healthcare and Biotechnology have grown tremendously worldwide, and have become a natural choice for companies - even for companies with very early stage developments, particularly in the United States.

However, this is still a strategy that is rarely executed by Spanish biotech companies, despite the fact that there is a much greater appetite for biotech investment and more mechanisms to access capital markets than ever before.

Euronext is an alternative that offers several markets adapted to the needs of each company, which could solve many of the usual problems for companies (lack of funding, excessive dependence on specialised investors) and for investors (lack of liquidity, basically!).

In this session, Susana de Antonio, Head of EU Tech Hub and representative in Spain of Euronext, will explain the options to access a variety of listed markets, from Euronext Access (initial market designed for technical listing) to Euronext regulated market,

The session will also be kindly joined by Paolo Pescetto, CEO of Innovative RFK, an Italian company who recently raised 2.3 million euros via Equity Crowdfunding and then went on to list the company on Euronext.

-> The presentation will be held in Spanish (Susana de Antonio) and English (Paolo Pescetto)

Agenda:

- 9.30 - Registration and Welcome speech: Daniel Oliver – Director at Capital Cell

- 9.35 - Main presentation: The Euronext option, by Susana de Antonio, Head of EU Tech Hub and Spain Representative – Euronext

- 10.00 - Company testimonial: Paolo Pescetto, CEO – Innovative-RFK

- 10.15 - Q&A session

Where can I contact the organizer if I have any questions?

Please contact Marc Sastre (marcsastre@capitalcell.net)